UP!
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: AGIO |
| Industry | Pharmaceuticals |
| Founded | 2008 (2008) |
| Headquarters | Cambridge, Massachusetts, United States |
|
Key people
|
David Schenkein (CEO) |
| Website | agios |
| Footnotes / references Foundation |
|
Agios Pharmaceuticals is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation by the company are IDH1 and IDH2. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.
In May 2016, the company announced it would launch partnership with Celgene, developing metabolic immuno-oncology therapies. The deal could net more than $1 billion for Agios.
In April 2017, the company raised $250 million in a new stock offering in anticipation of FDA approval for its first cancer drug.
As of April 2017, Agios' CEO was David Schenkein.
Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-01 | Future report Set alerts | |
| Q2 2022 | 2022-08-04 | -1.68 | -1.68 |
| Q1 2022 | 2022-05-05 | -1.74 | -1.74 |
| Q4 2021 | 2022-02-24 | -1.74 | -1.74 |
| Q3 2021 | 2021-11-03 | -1.56 | -1.56 |
| Q2 2021 | 2021-07-29 | -1.44 | -1.44 |
| Q1 2021 | 2021-04-29 | 26.95 | 26.95 |
| Q4 2020 | 2021-02-25 | -1.41 | -1.41 |
| Q3 2020 | 2020-11-05 | 0.00 | 0.00 |
| Q2 2020 | 2020-07-30 | -1.31 | -1.31 |
| 2016-06-13 | Reiterated Rating | Goldman Sachs | Hold | $46.00 |
| 2016-06-13 | Reiterated Rating | Janney Montgomery Scott | Neutral | $52.00 to $47.00 |
| 2016-06-13 | Upgrade | JPMorgan Chase & Co. | Neutral to Overweight | $50.00 to $62.00 |
| 2016-06-13 | Upgrade | Canaccord Genuity | Hold to Buy | $50.00 to $90.00 |
| 2016-06-13 | Reiterated Rating | Goldman Sachs Group Inc. | Hold | $46.00 |
| 2016-06-10 | Reiterated Rating | JPMorgan Chase & Co. | Hold | |
| 2016-06-09 | Reiterated Rating | Canaccord Genuity | Hold | $50.00 |
| 2016-05-24 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-05-19 | Reiterated Rating | Leerink Swann | Market Perform | $56.00 |
| 2016-05-18 | Reiterated Rating | Canaccord Genuity | Hold | $50.00 |
| 2016-05-18 | Boost Price Target | Credit Suisse | Outperform | $65.00 to $70.00 |
| 2016-05-18 | Boost Price Target | SunTrust | Buy | $57.00 to $65.00 |
| 2016-05-18 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-05-18 | Boost Price Target | Credit Suisse Group AG | Outperform | $65.00 to $70.00 |
| 2016-05-18 | Boost Price Target | SunTrust Banks Inc. | Buy | $57.00 to $65.00 |
| 2016-04-25 | Reiterated Rating | Credit Suisse | Buy | |
| 2016-03-31 | Reiterated Rating | JPMorgan Chase & Co. | Hold | |
| 2016-03-29 | Initiated Coverage | SunTrust | Buy | $57.00 |
| 2016-03-27 | Reiterated Rating | Credit Suisse | Buy | |
| 2016-03-04 | Reiterated Rating | Canaccord Genuity | Hold | $70.00 to $50.00 |
| 2016-03-01 | Initiated Coverage | Janney Montgomery Scott | Neutral | $43.00 |
| 2016-02-22 | Lower Price Target | Goldman Sachs | $72.00 to $47.00 | |
| 2016-02-19 | Reiterated Rating | Leerink Swann | Market Perform | $62.00 to $56.00 |
| 2016-02-19 | Lower Price Target | Credit Suisse | $75.00 to $66.00 | |
| 2016-01-20 | Initiated Coverage | Credit Suisse | Outperform | $75.00 |
| 2015-12-07 | Downgrade | Leerink Swann | Outperform to Market Perform | $105.00 to $62.00 |
| 2015-11-09 | Lower Price Target | Roth Capital | Neutral | $114.00 to $75.00 |
| 2015-11-09 | Reiterated Rating | Oppenheimer | Hold | |
| 2015-11-09 | Reiterated Rating | Oppenheimer Holdings Inc. | Hold | |
| 2015-10-26 | Lower Price Target | Leerink Swann | Outperform | $124.00 to $105.00 |
| 2015-10-21 | Reiterated Rating | Oppenheimer | Market Perform | |
| 2015-10-15 | Reiterated Rating | Canaccord Genuity | Hold | $93.00 to $70.00 |
| 2015-08-07 | Reiterated Rating | Canaccord Genuity | Hold | $93.00 |
| 2015-08-05 | Reiterated Rating | Roth Capital | Hold | $114.00 |
| 2015-07-22 | Initiated Coverage | Northland Securities | Outperform | $132.00 |
| 2015-07-02 | Upgrade | Desjardins | Hold to Buy | |
| 2015-06-15 | Lower Price Target | Canaccord Genuity | Hold | $103.00 to $93.00 |
| 2015-06-02 | Initiated Coverage | Citigroup Inc. | Neutral | $132.00 |
| 2015-05-08 | Initiated Coverage | MLV & Co. | Buy | $130.00 |
| 2015-04-30 | Downgrade | Canaccord Genuity | Buy to Hold | $163.00 to $103.00 |
| 2015-04-20 | Initiated Coverage | Oppenheimer | Market Perform | |
| 2015-02-18 | Set Price Target | Citigroup Inc. | Hold | $137.00 to $132.00 |
| 2015-02-18 | Boost Price Target | MLV & Co. | Buy | $123.00 to $130.00 |
| 2015-02-17 | Set Price Target | Canaccord Genuity | Buy | $163.00 |
| 2015-01-28 | Downgrade | Citigroup Inc. | Buy to Neutral | $93.00 to $137.00 |
| 2015-01-05 | Initiated Coverage | Roth Capital | Neutral | $114.00 |
| 2014-12-04 | Initiated | MLV & Co | Buy | $123 |
| 2014-12-04 | Initiated Coverage | MLV & Co. | Buy | $123.00 |
| 2014-12-02 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $60.00 to $90.00 |
| 2014-11-19 | Reiterated Rating | Canaccord Genuity | Buy | $97.00 to $111.00 |
| 2014-11-12 | Initiated Coverage | Canaccord Genuity | Buy | $97.00 |
| 2014-11-07 | Downgrade | Goldman Sachs | Buy to Neutral | |
| 2014-07-01 | Initiated Coverage | Citigroup Inc. | Buy | $58.00 |
| 2014-06-16 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $55.00 to $60.00 |
| 2014-04-07 | Boost Price Target | Leerink Swann | $51.00 to $65.00 | |
| 2014-04-07 | Upgrade | JPMorgan Chase & Co. | Neutral to Overweight | $40.00 to $55.00 |
| 2014-03-28 | Boost Price Target | JPMorgan Chase & Co. | $35.00 to $40.00 | |
| 2014-03-07 | Boost Price Target | Leerink Swann | $38.00 to $51.00 |
| 2016-06-13 | Reiterated Rating | Goldman Sachs | Hold | $46.00 |
| 2016-06-13 | Reiterated Rating | Janney Montgomery Scott | Neutral | $52.00 to $47.00 |
| 2016-06-13 | Upgrade | JPMorgan Chase & Co. | Neutral to Overweight | $50.00 to $62.00 |
| 2016-06-13 | Upgrade | Canaccord Genuity | Hold to Buy | $50.00 to $90.00 |
| 2016-06-13 | Reiterated Rating | Goldman Sachs Group Inc. | Hold | $46.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In AGIO 145 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Vanguard Group, Inc | 5.23M |
| WELLINGTON MANAGEMENT CO LLP | 5.15M |
| BlackRock Inc. | 4.79M |
| Rock Springs Capital Management LP | 3.06M |
| STATE STREET CORP | 2.63M |
| FIRST TRUST ADVISORS LP | 1.99M |
| Flagship Ventures 2007 General Partner LLC | 1.93M |
| Flagship Ventures Fund 2007, L.P. | 1.93M |
| ARMISTICE CAPITAL, LLC | 1.92M |
| FMR LLC | 1.91M |
| GOLDMAN SACHS GROUP INC | 1.67M |
| FARALLON CAPITAL MANAGEMENT LLC | 1.50M |
| JPMORGAN CHASE & CO | 1.49M |
| DIMENSIONAL FUND ADVISORS LP | 1.48M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.48M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Arch Venture Fund VII LP | 8.96% (3088590) | AGIO / BLUE / JUNO / RCPT / RTGN / SAGE / |
| Flagship Ventures Fund 2007, L.P. | 5.60% (1930369) | AGIO / EBIO / RCPT / |
| Celgene European Investment Co LLC | 5.39% (1856353) | AGIO / CELG / EPZM / |
| CELGENE CORP /DE/ | 3.99% (1374599) | AGIO / ALQA / CELG / XLRN / |
| STARR KEVIN P | 0.54% (184386) | AGIO / ALNY / SAGE / |
| Higgons John Duncan Chief Operating Officer | 0.35% (120834) | AGIO / |
| Tessier-Lavigne Marc | 0.29% (101009) | AGIO / PFE / REGN / |
| Cantley Lewis Clayton Jr. | 0.23% (79515) | AGIO / |
| Biller Scott Chief Scientific Officer | 0.17% (57196) | AGIO / |
| MARAGANORE JOHN | 0.14% (49764) | AGIO / ALNY / BLUE / RGLS / |
| Goddard Glenn Senior Vice President, Finance | 0.03% (10000) | AGIO / |
| Cole Douglas G. | 0.01% (2778) | AGIO / RCPT / TTPH / |
| Foster-Cheek Kaye I | 0.01% (2200) | AGIO / |
| Alenson Carman Principal Accounting Officer | 0.01% (2150) | AGIO / |
UM